PDCD1LG2 and cancer: Cisplatin induces TFEB nuclear translocation, upregulates downstream PD-L1 and PD-L2, and forms an immune-suppressive cancer microenvironment; this mediates cancer immune escape and drug resistance, and can be used to target TFEB inhibition to increase ovarian cancer cell cisplatin sensitivity (64).